Worries Around Sinopharm Resurface Following Low Antibody Tests
Worries around the Chinese Sinopharm vaccine have resurfaced after insufficient antibody levels were recorded in many people who received both vaccinations in Hungary. While those who defend the vaccine assert that people can still have cell immunity, there is increasing evidence that this is not the case. Those wishing to raise awareness on the issue have joined a Facebook group, sending letters to Prime Minister Viktor Orbán, Chief Medical Officer Cecília Müller, and Hungarian healthcare professionals.
There are more than 3.6 thousand members in the rapidly growing “People Vaccinated with Sinopharm with Negative Laboratory Tests,” closed Facebook group. The purpose of the group is to ensure testing and revaccination if necessary for people who have been vaccinated with the Sinopharm vaccine but have little to no antibodies in their immune system.
US Medical Journal: Sinopharm Effective Against Coronavirus
The Journal of the American Medical Association (JAMA) shared the entire documentation of the Sinopharm vaccine, developed by China National Biotec Group Company (CNBG). The study, overwhelmingly made up of younger, healthy male volunteers, concluded that the vaccine is 72.8 and 78.1 percent effective against the coronavirus.
The long-awaited phase three clinical trials of the Sinopharm vaccine have finally been shared, showing that it is effective. The large scale study involved 40,832 volunteers from the United Arab Emirates, Bahrain, Egypt, and Jordan.
Very Few Elders in Sinopharm Vaccine Clinical Trials
Participants were either given two doses within three weeks or a placebo. Two weeks before their second inoculation, significantly more non-vaccinated people had caught the virus than those who were vaccinated at least once.
Katalin Karikó, the Hungarian biochemist who was fundamental in the creation of Pfizer-BioNTech’s vaccine, is currently in Hungary until May 27. While her schedule and work responsibilities have kept her very busy, since she has arrived she has spoken at the Hungarian Academy of Science (MTA), given interviews to Hungarian media, and met with the rector of Semmelweis University, Béla Merkely.
At her speech for the 194th conference of the Hungarian Academy of Science (MTA), Katalin Karikó spoke about her career path, which started at the University of Szeged, and gave details on the scientific know-how of messenger ribonucleic acid (mRNA) technology. It was Karikó’s decades of hard work which led to this technology becoming the foundation for Pfizer-BioNTech’s coronavirus vaccine.
The World Health Organisation’s (WHO) approval of the Sinopharm vaccine is “a justification” for the Hungarian government’s vaccination policy, Human Resources Minister Miklós Kásler said on Friday evening, in reaction to WHO’s announcement.
“Hungary’s vaccination policy has been driven exclusively by health-care considerations, political or economic considerations did not play any role,” he said on Facebook.
Word has spread about a 12-month study being planned to test the efficacy of all vaccines currently authorized in Hungary. Despite the magnitude of the nation-wide experiment, the government has been relatively silent regarding its details. The Pécs University Clinical Center shared a publication inviting people to take part in a voluntary 12-month antibody-study of […]Continue reading
Béla Merkely supported the Chinese Sinopharm vaccine, arguing that, like Hungary's other vaccines, it provides effective protection against the coronavirus.